Related Tags >> FDA Phase III Cardiome antibiotic

Astellas News

Most Popular Astellas Story

Maxygen inks $180M deal with Astellas

September 19, 2008 — 9:50am ET | By John Carroll

Maxygen is pocketing a $10 million upfront fee from Japan's Astellas for marketing rights to its Maxy-4 therapies--a preclinical program focused on developing a next-generation CTLA4-Ig protein for... Read more...

Astellas Press Releases

PRESS RELEASE: Astellas to Acquire Agensys

Latest Headlines

Maxygen inks $180M deal with Astellas
September 19, 2008
Cardiome shares plunge on approvable letter
August 11, 2008
Astellas inks $537M deal for Agensys
November 27, 2007
FDA wants more data on Theravance antibiotic
October 22, 2007
SPOTLIGHT: Cardiome, Astellas get panel date
August 30, 2007
Nereus gains $45M in D-2 round for cancer drugs
August 9, 2007
Theravance trumpets positive results of mid-stage trial
June 26, 2007
Press Release: AtheroGenics to Present at JPMorgan Healthcare Conference
January 5, 2007
Cardiome, Astellas revise deal for RSD 1235
July 10, 2006
ALSO NOTED: Group backs Gardasil; Astellas halts program; and much more...
June 29, 2006
Ilypsa signs $92 million licensing deal
April 26, 2006
SPOTLIGHT: Daiichi Sankyo buys OTC business
March 30, 2006
ALSO NOTED: J&J sent back to do more research; Barrier Therapeutics wins FDA OK; and much more...
February 16, 2006
ALSO NOTED: Gilmartin to testify; Dr. Reddy's inks deal with Merck; and much more...
January 31, 2006
DEALS: Astellas pays Theravance $65M for antibiotic
November 9, 2005
Cardiome unveils dramatic results for atrial fibrillation therapy
September 29, 2005
CV Therapeutics touts heart-imaging drug's Phase III data
August 10, 2005
ALSO NOTED: FDA accepts Tarceva sNDA; Verus licenses Twinject; StemCells gains stake in ReNeuron; and much more...
July 5, 2005
ALSO NOTED: FDA studies blindness; Roche gets OK for HIV drug; FDA approves Zemplar; and much more...
May 26, 2005

Paid Research Reports